Curewize Health Ltd. commercializes leading-edge technologies that can significantly improve the overall survival and health of young cancer patients. Curewize was awarded an Israeli Office of Chief Scientist grant for the commercialization of ProALL and is seeking matching funding.
ProALL is a prognostic assay that can help improve ALL patients’ survival and quality of life by determining whether the patient needs a standard or intense treatment. ProALL solves several drawbacks of MRD, which are currently used to determine ALL patients risk based treatment group.
ProALL results are available 2 days from diagnosis vs 1-3 months from diagnosis with MRD.
Unlike MRD, ProALL is universal; there is no need to design the assay for each patient.
ProALL is performed in standard clinical labs; MRD is performed in a few labs with specific expertise. ProAll has proven monitoring ability and fits well with routine practice. ProALL and MRD can be used together for even higher accuracy.